3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Sarcoma
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Appendiceal Neoplasms
1
Interventions
Paclitaxel
115
Carboplatin
114
Cisplatin
46
Topotecan
43
Gemcitabine
31
Cyclophosphamide
31
Docetaxel
28
Bevacizumab
28
liposomal doxorubicin
27
Filgrastim
20
pembrolizumab
19
Peripheral Blood Stem Cell Transplantation
18
Taxes
15
Drug Therapy
15
Hyperthermic Intraperitoneal Chemotherapy
13
sargramostim
12
olaparib
12
Immunohistochemistry
11
Chemotherapy, Adjuvant
11
Surgical Procedures, Operative
10
Therapeutics
9
Flow Cytometry
9
Etoposide
9
oregovomab
8
niraparib
8
mirvetuximab soravtansine
8
Psychiatric Rehabilitation
8
Nivolumab
8
Amifostine
8
rucaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
Referral and Consultation
×
Gynecologic
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled